z-logo
Premium
Intestinal Resistance in the Experimental Enteric Infection of Mice with a Mouse Adenovirus
Author(s) -
Hashimoto Kazuo,
Okada Yasuo,
Tajiri Takashi,
Amano Hiroshi,
Aoki Nobuhiro,
Sasaki Shogo
Publication year - 1973
Publication title -
japanese journal of microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0021-5139
DOI - 10.1111/j.1348-0421.1973.tb00936.x
Subject(s) - antibody , virus , titer , virology , neutralizing antibody , biology , antibody titer , immunology , microbiology and biotechnology
The influence of cyclophosphamide (Cy) on the establishment and duration of the intestinal resistance against enteric infection with a mouse adenovirus, strain K87, was examined in inbred mice, strain DK1. When Cy (40 mg/kg/day) was administered to mice for 17 days from the time of virus challenge, a clear prolongation of viral growth and a delayed appearance of neutralizing (NT) antibody in the intestinal wall as well as in the serum were observed. When Cy (40 mg/kg/day, for 14 days) was administered after cessation of viral growth (4 to 6 weeks after virus challenge) and part of the mice were rechallenged with the virus, titers of NT antibody and immunoglobulins became significantly lower than those in control mice not treated with Cy, and regrowth of the virus was observed in eight out of twenty‐five Cy‐treated mice, regardless of the presence or absence of re‐challenge. In this experiment, antibody titers in the intestinal contents of eight virus‐positive mice were significantly lower than those of the remaining seventeen virus‐negative mice. The time when the decrease of intestinal NT antibody was maximum coincided with the time of the maximal frequency of viral regrowth. It was discussed that these facts might present an evidence to support the idea that the intestinal resistance was acquired through local NT antibody belonging to IgA in the intestinal tract.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here